Ibogaine and the future of healing with Trevor Millar and Jonathan Dickinson of Ambio Life Sciences

Ibogaine is framed as a next step for healing that could expand access to structured, medically guided addiction care. The discussion highlights how companies like Ambio Life Sciences position ibogaine as part of an evidence building pathway, connecting product development with clinical goals rather than treating it as only an underground treatment. The conversation also points to the broader future of psychedelic medicine: improving safety, creating clear therapeutic protocols, and translating promising science into scalable treatment options. It emphasizes why industry backed research and development matter for bringing ibogaine into mainstream clinical settings.